Prim S.A (PRM) | Stock Overview & Key Data
Prim S.A. | Mid-cap | Healthcare
Prim S.A. | Mid-cap | Healthcare
Prim S.A Performance Comparison
Stock Range
Today's Range
Low: €13.10
High: €13.35
on September 18, 2025
52 Week Range
Low: €9.06
High: €13.40
on April 7, 2025
on September 17, 2025
All-Time High: €18.94 on February 20, 2006
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€227.2M
EPS
0.91
P/E Ratio (TTM)
14.29
Forward P/E
10.57
P/B Ratio
1.67
PEG Ratio
10.57
Div. Yield
N/A
ROE
11.21%
Beta
N/A
Debt to Equity
17.29
Financial Highlights
Profitability
Gross Margin
50.44%
Operating Margin
10.20%
Profit Margin
6.05%
Returns and Earnings
Return on Assets (TTM)
5.48%
Return on Equity (TTM)
11.21%
EBITDA
€27.1M
Net Income (TTM)
€14.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€14.15
Quarterly Revenue Growth (YoY)
5.00%
Quarterly Earnings Growth (YoY)
53.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Prim S.A PRM | 227.16M Mid-cap | 3.92% | 10.42% | 16.23% | 31.19% | 36.60% | 24.41% | 12.77% | 45.29% |
| Grifols, S.A GRF | 7.38B Large-cap | -2.70% | -5.33% | 14.64% | 23.57% | 25.79% | 21.06% | 18.76% | -51.01% |
| Laboratorios ROVI | 3.04B Large-cap | -2.49% | 2.45% | 6.54% | 11.29% | -8.36% | -19.93% | 40.58% | 87.38% |
| Almirall S.A ALM | 2.41B Large-cap | 0.00% | -0.53% | 4.26% | 8.37% | 34.37% | 34.21% | 24.28% | 12.94% |
| Pharma Mar S.A PHM | 1.59B Large-cap | 1.10% | 3.25% | 7.71% | -2.73% | 9.12% | 83.43% | 60.22% | -14.70% |
| Faes Farma S.A FAE | 1.31B Large-cap | -2.79% | -1.42% | -7.11% | 27.05% | 19.09% | 12.97% | 12.97% | 17.09% |
Ownership & Short Interest
Insider Ownership
43.74%
Institutional Ownership
11.97%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4K
Average 90-Day Volume
4K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PRM's 52-week high and low?
- In the last 52 weeks, Prim S.A reached a high of €13.40 (on September 17, 2025) and a low of €9.06 (on April 7, 2025).
- What is the market cap and P/E ratio for PRM?
- Curious about Prim S.A's size and valuation? Its market capitalization stands at 227.16M. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.29, and the forward P/E (looking ahead) is 10.57.
- Does PRM pay dividends? If so, what's the yield?
- As for dividends, Prim S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Prim S.A's main competitors or similar companies to consider before investing?
When looking at Prim S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Grifols, S.A
GRF7.38B Healthcare Drug Manufacturers - General 21.06% 18.76% Laboratorios
ROVI3.04B Healthcare Drug Manufacturers - Specialty & Generic -19.93% 40.58% Almirall S.A
ALM2.41B Healthcare Drug Manufacturers - Specialty & Generic 34.21% 24.28% Pharma Mar S.A
PHM1.59B Healthcare Biotechnology 83.43% 60.22% Faes Farma S.A
FAE1.31B Healthcare Drug Manufacturers - Specialty & Generic 12.97% 12.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Prim S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Prim S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 11.21%, the Debt to Equity ratio from the most recent quarter is 17.29, and its Gross Profit Margin stands at 50.44%.
- What is the recent revenue and earnings growth for PRM?
- Looking at Prim S.A's growth, its revenue over the trailing twelve months (TTM) was €241M. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.00%, and quarterly earnings saw a YoY growth of 53.70%.
- How much of PRM stock is held by insiders and institutions?
- Wondering who owns Prim S.A stock? Company insiders (like executives and directors) hold about 43.74% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 11.97%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.